RxDoctor Payments Data

Takela Anderson

Family · Greensboro, NCNPI 1023342144

Payments from drug & device makers

$10,102in general payments, 2019–2025

Across 526 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Neurocrine Biosciences, Inc.$873
  • Otsuka America Pharmaceutical, Inc.$666
  • Teva Pharmaceuticals USA, Inc.$613
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$9,99399%
  • Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,102 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$10,381
Medicare patients
34
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$30,470
FarxigaDapagliflozin Propanediol27$27,118
OzempicSemaglutide14$24,573
TrulicityDulaglutide16$24,002
RybelsusSemaglutide25$23,530
JardianceEmpagliflozin33$23,214
LinzessLinaclotide40$22,051
KerendiaFinerenone24$17,507
EliquisApixaban23$12,133
Synjardy XrEmpagliflozin/Metformin Hcl15$9,415
Xigduo XrDapaglifloz Propaned/Metformin19$9,244
EntrestoSacubitril/Valsartan15$8,595
VascepaIcosapent Ethyl27$7,302
SymbicortBudesonide/Formoterol Fumarate18$4,361
Albuterol Sulfate HfaAlbuterol Sulfate94$3,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$1,004$54,983115 claims
Novo NordiskOzempic, Rybelsus$1,145$48,10339 claims
Boehringer IngelheimJardiance, Synjardy Xr$257$32,62948 claims
AstraZenecaFarxiga, Symbicort$105$31,47845 claims
AbbVieLinzess$1,406$22,05140 claims
BayerKerendia$448$17,50724 claims
PfizerEliquis$428$12,13323 claims
NovartisEntresto$20$8,59515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →